



**PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF
2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS
(THE “TRANSPARENCY LAW”)**

GHENT, Belgium, 12 February 2018 – Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from BlackRock, Inc. on 7 February 2018.

BlackRock, Inc. (taking into account the holdings of its subsidiary undertakings) notified Ablynx that it has upward crossed the 3% threshold since 6 February 2018 and now holds a total of 2,268,050 voting securities of Ablynx, representing 3.02% of the current 75,065,990 outstanding voting rights of Ablynx.

The notification contains the following information:

- **Reason for the notification:** acquisition or disposal of financial instruments that are treated as voting securities
- **Notification by:** a parent undertaking or a controlling person
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.

- **Transaction date:** 6 February 2018
- **Threshold that is crossed:** 3%
- **Denominator:** 75,065,990
- **Details of the notification:**

Name of select subsidiaries of BlackRock	% of voting rights	% of voting rights held through financial instruments*	Total of both
BlackRock (Netherlands) B.V.	0.01%		0.01%
BlackRock Advisors (UK) Limited	0.08%	0.32% ¹	0.40%
BlackRock Asset Management Canada Limited	0.00%	0.01% ¹	0.01%
BlackRock Fund Advisors	0.27%	0.50% ¹	0.77%
BlackRock Institutional Trust Company, National Association	0.22%	0.29% ¹ / 0.09% ²	0.60%
BlackRock Investment Management (Australia) Limited	0.00%		0.00%
BlackRock Advisors, LLC	0.00%	0.15% ²	0.15%

BlackRock Financial Management, Inc.		0.48% ²	0.48%
BlackRock Investment Management, LLC		0.60% ²	0.60%
TOTAL	0.59%	2.44%	3.02%

* Type of financial instrument: ¹'Securities lent' and ²'Contract for Difference'

- **Chain of controlled undertakings through which the holding is effectively being held:** Please see the full chain of control in the Transparency Notification.

A full version of the transparency notification is available on Ablynx website, under the section [Investors](#).

The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the development of [Nanobodies](#), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than [45 proprietary and partnered programmes](#) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Lies Vanneste

Director IR

t: +32 (0)9 262 0137

m: +32 (0)498 05 35 79

e: lies.vanneste@ablynx.com

 [@AblynxABLX](#)

Ablynx media relations:

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji

t: +44 (0)20 3709 5700

e: ablynx@consilium-comms.com

Joele Frank, Wilkinson Brimmer Katcher

Dan Katcher or Joseph Sala

t: +1 212-355-4449